Kepler Capital analyst Maja Pataki maintained a Hold rating on Grifols SA (NASDAQ:GRFS) on Friday, setting a price target of EUR24.2, which is approximately 82.19% above the present share price of $15.68.
Pataki expects Grifols SA to post earnings per share (EPS) of $0.00 for the third quarter of 2021.
The current consensus among 4 TipRanks analysts is for a Moderate Buy rating of shares in Grifols SA, with an average price target of $28.63.
The analysts price targets range from a high of $35.42 to a low of $17.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $1.31 billion and a net profit of $248.43 million. The company's market cap is $10.64 billion.
According to TipRanks.com, Kepler Capital analyst Maja Pataki is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -11.8% and a 35.40% success rate.
Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.